SynthesisPediatric blood & cancer2025
Neurological, Neuropsychological, and Social Outcomes in Pediatric Patients Diagnosed With Cerebellar Mutism Syndrome: A Systematic Review.
Synthesis in Pediatric blood & cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCerebellar mutism syndrome (CMS) is a postsurgical complication following posterior fossa tumor resection. This review explores long-term neurological, neuropsychological, and social outcomes of children with CMS.
methodsA search was performed across multiple databases, focusing on terms related to neoplasms, postoperative complications, and mutism. Selected studies included individuals less than 18 years of age who developed CMS following posterior fossa tumor removal, and developed at least one neurological, neuropsychological, or social outcome.
resultsAmong 2514 publications, 34 studies were included, describing 631 patients aged 1-25.7 years (median = 12 patients; range: 5-107 patients). The prevalence of CMS ranged from 3.7% to 63%, with a median follow-up of 26.5 months (ranging from 2 months to 14.2 years). Ataxia was the most common neurologic outcome reported in 17 studies. Five of nine studies assessing cognitive outcomes noted significantly lower full-scale intelligence quotient/general intellectual ability scores among CMS patients. Emotional changes were observed in 40%-100% of participants across 23 studies.
conclusionsCMS survivors face ongoing neurological, neuropsychological, and behavioral challenges, impacting their quality of life and highlighting the need for advancements in surgical techniques and rehabilitation interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.